Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore
Mankind Pharma set out an expansion in a quarterly results development.
· Economic Times Markets, ET Stocks
Mankind Pharma shares jumped nearly 8% after the company reported a 38% year-on-year rise in Q2 profit to Rs 716 crore. Revenue grew 17%, supported by domestic and export growth, while EBITDA margins expanded 210 basis points.
The analysis
Mankind Pharma reported Rs 716 crore, with movement of 8%, 38% and 17% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +9.0% on the day at ₹2,520.70, and has returned -7.8% over three months. It sits 4% below its 52-week high. The pharma & healthcare sector has moved -3.1% over the same period, so Mankind Pharma is running 4.7 points behind its peers.
For Mankind Pharma, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Mankind Pharma (MANKIND), in Pharma & Healthcare.
- Over three months: Mankind Pharma -7.8% against Pharma & Healthcare -3.1% (4.7 points behind).
- Trading well above normal today: Mankind Pharma at 4.1 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Mankind PharmaMANKIND · Pharma & Healthcare | ₹2,520.70 | +9.0% | -6.6% | -7.8% | -3.7% | 4.1× | — |
Pharma & Healthcare
1M -8.3% · 3M -3.1%
Mankind Pharma
Prices as of 27 Oct 2026, 14:42 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business
Q2 results 2026 today, schedule: Paytm, Tata Con, REC among 90 firms to announce quarterly earnings | Full list
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore, revenue slips 2%
Acutaas Chemicals rallies 13%; hits record high on strong Q2 results
Q2 Results Live: L&T, Maruti Suzuki, Tata Steel, Cipla, SBI Life, Bajaj Auto, Indus Towers, Waaree Energies In Focus